LONZA GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 526.4 CHF | +1.19% |
|
+3.13% | +48.83% |
| Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... |  |
| Apr. 18 | Lonza Finance Launches EUR1 Billion 12-Year Euro Bond | DJ |
Presenter SpeechPierre-Alain Ruffieux (Executives)So good morning, good afternoon, everybody. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;
- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients;
- small molecule drug substances (13.2%);
- technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%);
- other (2.8%).
Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
2024-05-12
- Ex-dividend day for final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
526.4
CHF
Average target price
573.9
CHF
Spread / Average Target
+9.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +48.83% | 41.8B | |
| +23.37% | 46.71B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B | |
| +20.99% | 11.58B |
- Stock Market
- Equities
- LONN Stock
- News Lonza Group AG
- Transcript : Lonza Group Ltd - Analyst/Investor Day